Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

AEZS opened at $1.96 on Friday. Aeterna Zentaris has a 52-week low of $1.36 and a 52-week high of $3.38. The stock has a market capitalization of $9.53 million, a PE ratio of -0.57 and a beta of 1.57. The stock’s 50 day moving average price is $1.95 and its 200-day moving average price is $1.90.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.